Amodei says AI biology will follow math's exponential curve. The evidence is a forecast.

Anthropic chief executive Dario Amodei used an essay-length X post on September 23 to make a forecast, not a report: AI for biology, he wrote, is on the same exponential trend that mathematics has just run. The post went up roughly twenty-five minutes after Anthropic's own announcement of a Claude-led enzyme-system find, covered here the next day. It drew about 28,500 likes and 3,200 reposts. That is reach, not evidence.

The curve, asserted

Amodei's argument is a pattern claim. "We've repeatedly seen a pattern where AI performance in new intellectual domains goes from weak to superhuman in a matter of a few years," he writes in the post. His evidence is a timeline: average high-school math in 2023, the best high-school competitions in 2024, minor open problems in 2025, "more significant" ones in early 2026, and "the top few open problems in all of mathematics" by late 2026. No benchmark, paper or dataset accompanies the list. The math progression arrives as settled history from the person best placed to know it, before the trend is stretched over a second field.

The bottleneck he concedes

He grants the obvious objection himself. Math "can be done purely theoretically, while biology requires experimentation," and some read that as a ceiling. He does not. Humans can collaborate with models to run experiments and validate results in weeks, he writes, and Claude may "eventually" drive lab equipment directly "with appropriate safeguards" - not today. His own caveats undercut the headline: the discovery's "precise function, biotechnological utility (if any), or level of significance is not yet clear." He also volunteers prior art: work on reverse transcriptase systems goes back decades, and a Stanford team independently described a similar but distinct system. On clinical speed he is precise where the viral version is not: more candidates mean "an increase in throughput even though latency remains." Throughput is not latency, and the trials that gate medicine are untouched.

How it landed, and what would settle it

The reception leaned sceptical. On r/singularity the thread ran to roughly 435 points and 116 comments, one of which asked the plain question: "What's the discovery? This reads like they are doing experiments and dont yet know if this is anything useful." The most-liked X reply, from @simonmaechling, drew the same line: "Finding something interesting isn't the same as understanding it... So now comes the boring part. Make it. Test it. Break it. Repeat it." Settling the trajectory claim needs artifacts, not posts: independent replication of the enzyme system by a group outside Anthropic, a benchmark for biology-discovery tasks run by someone other than the vendor, and published lab results from other groups. Until those exist, weak-to-superhuman is a projection from an interested party.